Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma

References

• Shiels MS, Pfeiffer RM, Besson C, et al. Trends in primary central nervous system lymphoma incidence and survival in the U.S. Br. J. Haematol. 2016;174(3):417–424. doi:10.1111/bjh.14073
   PubMed Web of Science ®Google Scholar
• Han CH, Batchelor TT. Diagnosis and management of primary central nervous system lymphoma. Cancer. 2017;123(22):4314–4324. doi:10.1002/cncr.30965
   PubMed Web of Science ®Google Scholar
• Chiavazza C, Pellerino A, Ferrio F, et al. Primary CNS lymphomas: challenges in diagnosis and monitoring. Biomed. Res. Int. 2018;2018:1–16. doi:10.1155/2018/3606970
   Web of Science ®Google Scholar
• Schaff LR, Grommes C. Primary central nervous system lymphoma. Blood. 2022;140(9):971–979. doi:10.1182/blood.2020008377
   PubMed Web of Science ®Google Scholar
• Grommes C, DeAngelis LM. Primary CNS lymphoma. J. Clin. Oncol. 2017;35(21):2410–2418. doi:10.1200/JCO.2017.72.7602
   PubMed Web of Science ®Google Scholar
• Mendez JS, Ostrom QT, Gittleman H, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro. Oncol. 2018;20(5):687–694. doi:10.1093/neuonc/nox187
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Central nervous system cancers (Version 2.2019). [ Accessed 15 August 2021]. Available from: http://medi-guide.meditool.cn/ymtpdf/539E4DAA-3FE5-BA65-06CC-E497DB9B1857.pdf
   Google Scholar
• Lesueur P, Damaj G, Hoang-Xuan K, et al. Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study. Blood Adv. 2022;6(16):4807–4815. doi:10.1182/bloodadvances.2022007011
   PubMed Web of Science ®Google Scholar
• Tsang M, Rubenstein JL, Pulczynski EJ. Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative review. Ann. Lymphoma 2021;5:25. doi:10.21037/aol-20-43
   PubMedGoogle Scholar
• Bairey O, Taliansky A, Glik A, et al. A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma. Cancer 2023;129(24):3905–3914. doi:10.1002/cncr.34985
   PubMed Web of Science ®Google Scholar
• Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC Network. Neuro. Oncol. 2016;8(9):1297–1303. doi:10.1093/neuonc/now033
   Google Scholar
• Nayak L, Batchelor TT. Recent advances in treatment of primary central nervous system lymphoma. Curr. Treat. Options Oncol. 2013;14(4):539–552. doi:10.1007/s11864-013-0252-6
   PubMed Web of Science ®Google Scholar
• Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J. Clin. Oncol. 2016;26(15):2512–2518. doi:10.1200/JCO.2007.13.5533
   Google Scholar
• Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11(11):1036–1047. doi:10.1016/S1470-2045(10)70229-1
   PubMed Web of Science ®Google Scholar
• Nguyen PL, Chakravarti A, Finkelstein DM, et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J. Clin. Oncol. 2005;23(7):1507–1513. doi:10.1200/JCO.2005.01.161
   PubMed Web of Science ®Google Scholar
• Hottinger AF, DeAngelis LM, Yahalom J, et al. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma. Neurology. 2007;69(11):1178–1182. doi:10.1212/01.wnl.0000276986.19602.c1
   PubMed Web of Science ®Google Scholar
• Khimani NB, Ng AK, Chen YH, et al. Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy. Ann. Oncol. 2011;22(4):979–984. doi:10.1093/annonc/mdq548
   PubMed Web of Science ®Google Scholar
• Kiefer T, Hirt C, Späth C, et al. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study. Ann. Oncol. 2012;23(7):1809–1812. doi:10.1093/annonc/mdr553
   PubMed Web of Science ®Google Scholar
• Stewart J. Imbruvica FDA approval history; 2021. Available from: https://www.drugs.com/history/imbruvica.html
   Google Scholar
• Chen F, Pang D, Guo H, et al. Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use. Cancer Med. 2020;9(22):8676–8684. doi:10.1002/cam4.3499
   PubMed Web of Science ®Google Scholar
• Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network. Eur. J. Cancer. 2019;117:121–130. doi:10.1016/j.ejca.2019.05.024
   PubMed Web of Science ®Google Scholar
• Grommes C, Wolfe J, Gavrilovic I, et al. Phase II of single-agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL). Blood 2018;132(Suppl. 1):2965–2965. doi:10.1182/blood-2018-99-118538
   Google Scholar
• Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96–07. J. Clin. Oncol. 2003;21(6):1044–1049. doi:10.1200/JCO.2003.03.036
   PubMed Web of Science ®Google Scholar
• Enting RH, Demopoulos A, DeAngelis LM, et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63(5):901–903. doi:10.1212/01.WNL.0000137050.43114.42
   PubMed Web of Science ®Google Scholar
• Study of oral PQR309 patients with advanced solid tumors [Internet]. ClinicalTrials.gov identifier: NCT02483858 Updated March 22, 2019. [ Accessed 15 March 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT02483858
   Google Scholar
• Du S, Bota D, Kong XT. Successful consolidation/maintenance therapy with single agent ibrutinib for primary CNS lymphoma after initial induction therapy. Neurol. Int. 2022;14(3):574–580. doi:10.3390/neurolint14030046
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N. Engl. J. Med. 2019;381(5):432–443. doi:10.1056/NEJMoa1817073
   PubMed Web of Science ®Google Scholar
• Treon SP, Meid K, Gustine J, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia. J. Clin. Oncol. 2021;39(6):565–575. doi:10.1200/JCO.20.00555
   PubMed Web of Science ®Google Scholar
• Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood 2019;133(5):436–445. doi:10.1182/blood-2018-09-875732
   PubMed Web of Science ®Google Scholar
• Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7(9):1018–1029. doi:10.1158/2159-8290.CD-17-0613
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell 2017;31(6):833–843. doi:10.1016/j.ccell.2017.04.012
   PubMed Web of Science ®Google Scholar